NCT04592874

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 356 (actual)
• Sponsor: Alector Inc. · Industry
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.

Detailed description

This is a phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 administered intravenously in participants with Early Alzheimer's Disease.

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	AL002	Administered via intravenous (IV) infusion
DRUG	Placebo	Administered via intravenous (IV) infusion

Timeline

• Start date: 2021-01-22
• Primary completion: 2024-08-19
• Completion: 2024-09-12
• First posted: 2020-10-19
• Last updated: 2025-10-29
• Results posted: 2025-10-29

Locations

87 sites across 12 countries: United States, Argentina, Australia, Canada, France, Germany, Italy, Netherlands, New Zealand, Poland, Spain, United Kingdom

Regulatory

• FDA-regulated drug study